Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial

  title={Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial},
  author={Barbara Schmidt},
  pages={208 - 213}
  • B. Schmidt
  • Published 1 September 2005
  • Medicine
  • Neonatology
Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500–1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term… 

Figures and Tables from this paper

Long-term effects of caffeine therapy for apnea of prematurity.
Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight.
Caffeine therapy for apnea of prematurity.
Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight and reduced weight gain temporarily.
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years.
Ca # eine therapy for apnoea of prematurity in very low-birthweight infants
The CAP trial investigators showed for the first time that neonatal ca"eine therapy reduces the rates of important short and long-term morbidities such as bronchopulmonary dysplasia, severe retinopathy of prematurity, cerebral palsy and cognitive delay.
Caffeine in preterm infants: where are we in 2020?
It is speculated that with increased understanding of caffeine and its metabolism, a more refined respiratory management of preterm infants is feasible, leading to an overall improvement in patient outcome.
Current management of apnea in premature infants: is caffeine the magic bullet?
Caffeine therapy for apnoea of prematurity: Pharmacological treatment
A review of the pharmacokineƟ cs of caff eine and its cellular eff ect on the physiology of newborns with apnoea and some intriguing possibiliƟ es, such as the protecƟ ve on the brain and lungs are reported.
Prevention and treatment of bronchopulmonary dysplasia: current status and future prospects
Owing to potential short- and long-term effects, postnatal corticosteroids should be restricted to the most severe manifestations of BPD.
Nonventilatory Strategies for Prevention and Treatment of Bronchopulmonary Dysplasia – What Is the Evidence?
The evidence for a number of mainly drug-related strategies to prevent or treat bronchopulmonary dysplasia (BPD), including oxygen supplementation, anti-inflammatory drugs, and antioxidants have not been proven effective yet.
Differential diagnosis of apneas in preterm infants
The interruption of the Aminophylline treatment and setting up an antireflux regimen were recommended and had a positive effect: the frequency of alarm signals decreased within 48 h by a statistically significant 50%.


Historical Perspectives: Use of Methylxanthines in the Management of Apneic Attacks in the Newborn
During 1969, a preterm baby in the special care unit developed numerous apneic attacks that lasted 30 seconds or longer and were associated with periods of bradycardia and hypoxia, and died 18 days after birth.
Controversies surrounding xanthine therapy.
Effect of Caffeine on Oxygen Consumption and Metabolic Rate in Very Low Birth Weight Infants With Idiopathic Apnea
Long-term administration of caffeine in preterm infants is associated with an increase in oxygen consumption and with a reduction of weight gain, which may have implications for clinical practice as nutritional regimens need to be adjusted during this therapy.
Metabolic and respiratory effects of theophylline in the preterm infant
After theophylline treatment, preterm infants had faster respiration, lower transcutaneous CO2, and improved static respiratory compliance without increased physical activity, which could be detrimental to the growth of the preterm infant.
Oxygen consumption in apneic premature infants after low‐dose theophylline
This dose of theophylline is effective in idiopathic apnea of prematurity and acts as a metabolic stimulant in the premature infant and increases in .
Preterm outcomes research: a critical component of neonatal intensive care.
  • M. Allen
  • Medicine
    Mental retardation and developmental disabilities research reviews
  • 2002
Ongoing longterm preterm neurodevelopmental studies, analysis of changes in outcomes over time and among centers, and evaluation of the longterm safety, efficacy and effectiveness of many perinatal and neonatal management strategies and proposed neuroprotective agents are all necessary for further medical and technological advances in neonatal intensive care.
Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea.
Findings support the hypothesis that apnea in premature infants is related to an immature respiratory center characterized by a decreased output, and Aminophylline probably increases respiratory center output by lowering the threshold of the central chemorecepter to CO2.
Cognitive function in preterm infants: no simple answers.
Findings suggest some reasons for optimism regarding the cognitive outcome in VLBW children, but also highlights several potentially problematic issues found in follow-up studies.
Outcome at 5–6 years of prematurely born children who received morphine as neonates
Exposure to morphine in the neonatal period to facilitate mechanical ventilation does not seem to have any adverse effects on intelligence, motor function, or behaviour when these children are assessed at 5–6 years of age.
Development and evaluation of a follow up assessment of preterm infants at 5 years of age
Even after standardised and thorough assessment, paediatricians may overlook impairments for cognitive, motor, and behavioural development in preterm survivors of neonatal intensive care formerly considered non-disabled.